Brain cannabinoid receptor (CB1) antagonist. Prepn: F. Barth et al., EP 576357; eidem., US 5624941 (1993, 1997 both to Sanofi); H. H. Seltzman et al., J. Chem. Soc. Chem. Commun. 1995, 1549; and pharmacology: A. K. Dutta et al., Med. Chem. Res. 5, 54 (1994). Receptor antagonist activity: M. Rinaldi-Carmona et al., FEBS Lett. 350, 240 (1994). Clinical trial in blockade of effects of smoked marijuana: M. A. Huestis et al., Arch. Gen. Psychiatry 58, 322 (2001). Clinical trials in obesity: L. F. Van Gaal et al., Lancet 365, 1389 (2005); J.-P. Després et al., N. Engl. J. Med. 353, 2121 (2005). Review of therapeutic potential in obesity and drug addiction: M. A. M. Carai et al., Life Sci. 77, 2339-2350 (2005).
Antiobesity agent.
Antiobesity Agent